TEMPE, Ariz., March 5, 2009 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) today announced publication of results from the first data group of a pre-clinical study demonstrating that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, showed a statistically significant cardioprotective benefit in a model of acute myocardial infarction (AMI or heart attack).
